Data on the association between CTRP1 and future major adverse cardiovascular events in patients undergoing coronary angiography. by Muendlein, Axel et al.
Data in brief 25 (2019) 104109
s
o
u
r
c
e
:
 
ht
tp
s:
//
do
i.
or
g/
10
.7
89
2/
bo
ri
s.
13
53
47
 
| 
do
wn
lo
ad
ed
: 
4.
12
.2
01
9Contents lists available at ScienceDirect
Data in brief
journal homepage: www.elsevier .com/locate/dibData ArticleData on the association between CTRP1 and
future major adverse cardiovascular events in
patients undergoing coronary angiography
Axel Muendlein a, Andreas Leiherer a, b, c,
Christoph Saely a, c, d, e, Janine Ebner a, b, Kathrin Geiger a,
Eva Maria Brandtner a, Alexander Vonbank a, d,
Peter Fraunberger b, Heinz Drexel a, c, e, f, *
a Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria
b Medical Central Laboratories, Feldkirch, Austria
c Private University of the Principality of Liechtenstein, Triesen, Liechtenstein
d Department of Medicine and Cardiology, Academic Teaching Hospital Feldkirch, Feldkirch, Austria
e Division of Angiology, Swiss Cardiovascular Center, University Hospital of Bern, Bern, Switzerland
f Drexel University College of Medicine, Philadelphia, PA, USAa r t i c l e i n f o
Article history:
Received 24 April 2019
Received in revised form 17 May 2019
Accepted 28 May 2019
Available online 7 June 2019
Keywords:
Major adverse cardiovascular events
CTRP1
Risk factor
Adipokine
Prospective studyDOI of original article: https://doi.org/10.1016/
* Corresponding author. Vorarlberg Institute for
E-mail address: heinz.drexel@extern.insel.ch (H
https://doi.org/10.1016/j.dib.2019.104109
2352-3409/© 2019 The Author(s). Published by E
creativecommons.org/licenses/by/4.0/).a b s t r a c t
This article provides additional data on the association of the new
adipokine CTRP1 with the incidence of future major adverse car-
diovascular events in a prospective cohort of patients undergoing
coronary angiography. In this regard, multivariable Cox propor-
tional hazards models taking into account cardiac risk markers are
presented. Additionally, data on the impact of baseline variables
including metabolic traits and co-morbidities on the incidence of
future major adverse cardiovascular events are shown. This data
article is associated to the research article titled ‘The Novel Adi-
pokine CTRP1 is Signiﬁcantly Associated with the Incidence of
Major Adverse Cardiovascular Events’ Muendlein et al., 2019.
© 2019 The Author(s). Published by Elsevier Inc. This is an open
access article under the CC BY license (http://creativecommons.
org/licenses/by/4.0/).j.atherosclerosis.2019.04.222.
Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria.
. Drexel).
lsevier Inc. This is an open access article under the CC BY license (http://
Speciﬁcations table
Subject area Medicine, Clinical Research
More speciﬁc subject
area
Cardiology, Epidemiology, Biomarkers
Type of data Table
How data was
acquired
Serum CTRP1 levels were determined using a commercial enzyme-linked immunosorbent assay
(ELISA) kit (Biovendor, Czech Republic) together with a DTX 880 Multimode Detector (Beckman
Coulter, CA, U.S.A.). Patient data were acquired from national registries and review of patient
registries. Hazard ratios were derived from univariable and multivariable Cox proportional hazards
models using SPSS 25.0 for Windows.
Data format Analyzed data
Experimental factors Plasma CTRP1 levels were measured in 539 patients undergoing coronary angiography. These patients
were prospectively followed, and major adverse cardiovascular events cardiovascular events were
recorded for up to 8 years.
Experimental
features
CTRP1 plasma concentrations were measured by ELISA
Data source location Feldkirch, Austria
Data accessibility Data is with this article. Raw data are made available for further investigations in collaborative studies.
Related research
article
A. Muendlein, A. Leiherer, C.H. Saely, J. Ebner, K. Geiger, EM Brandtner, A. Vonbank, P. Fraunberger, H.
Drexel, The Novel Adipokine CTRP1 is Signiﬁcantly Associated with the Incidence of Major Adverse
Cardiovascular Events, Atherosclerosis. 286 (2019). https://doi.org/10.1016/j.atherosclerosis.2019.04.
222 [1].
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 The data presented here further characterize included patients by showing the impact of baseline variables on the
incidence ofmajor adverse cardiovascular events in patients undergoing coronary angiography, whichmay differ from the
general population.
 The data presented here stressed the impact of CTRP1 on future cardiovascular risk beyond its association with traditional
coronary risk factors and, therefore, may stimulate further research on the role of CTRP1 in the development of cardio-
vascular disease.
 These data are important, because the existing literature about CTRP1 is still limited, and therefore, they particularly
extend the knowledge regarding the association between CTRP1 and cardiovascular disease.1. Data
A signiﬁcant association between CTRP1 and major adverse cardiovascular events (MACE) in pa-
tients undergoing coronary angiography has been reported in the associated research article [1]. In
addition to the baseline characteristics of the selected study population given in the main article, Table
1 of this article shows the impact of most baseline variables on the incidence of MACE. Table 2 shows
further data regardingmultivariable Cox proportional hazardsmodels adjusting for age, sex, bodymass
index, type 2 diabetes mellitus, signiﬁcant coronary artery disease, hypertension, smoking, LDL
cholesterol, HDL cholesterol, and estimated glomerular ﬁltration rate and additionally for the extent of
coronary artery disease as well as the percentage of left ventricular ejection fraction (model a) or in-
ﬂammatory markers including ﬁbrinogen and C-reactive protein (model b).2. Experimental design, materials and methods
The present dataset included 539 consecutive Caucasian patients, who were referred to elective
coronary angiography for the evaluation of established or suspected stable CAD at the academic
teaching hospital Feldkirch, Austria. Baseline characteristics were obtained as described in the asso-
ciated main article [1] and in previous reports [2,3]. In short, the extent of atherosclerosis was deﬁned
as the number of 50% lesions. Left ventricular functionwas assessed by 2D echocardiography. Venous
blood samples were collected after an overnight fast of 12 h prior to angiography and laboratory
measurements were performed from fresh serum or plasma samples or from serum or plasma samples
Table 1
Impact of baseline variables on the incidence of major adverse cardiovascular events.
HR (95%CI) p-value
Age (years) 1.20 [0.96e1.49] 0.116
Male gender 0.99 [0.68e1.43] 0.945
BMI (kg/m2) 0.86 [0.72e1.04] 0.862
Metabolic syndrome 1.33 [0.94e1.88] 0.111
Type 2 diabetes mellitus 1.76 [1.23e2.50] 0.002
Hypertension 1.12 [0.72e1.77] 0.613
Smoking 1.21 [0.84e1.74 ] 0.302
LDL-Cholesterol (mg/dl) 0.84 [0.71e1.00] 0.049
HDL-Cholesterol (mg/dl) 0.74 [0.62e0.90] 0.002
Triglycerides (mg/dl) 1.06 [0.88e1.26] 0.550
eGFR (ml/min/1.73m2) 0.70 [0.58e0.85] <0.001
NAFLD 1.14 [0.79e1.65] 0.482
Signiﬁcant CAD 1.65 [1.12e2.44] 0.012
Extent of CAD 1.15 [1.05e1.26] 0.002
LVEF (%) 0.61 [0.51e0.73] <0.001
C-reactive protein (mg/dl) 1.46 [1.23e1.73] <0.001
Fibrinogen (mg/dl) 1.22 [1.01e1.47] 0.036
BNP (pg/dl) 1.51 [1.31e1.75] <0.001
Results of univariate Cox regression analysis. Age, BMI, LDL-C, HDL-C, triglycerides, eGFR, LVEF, C-reactive
protein, ﬁbrinogen, and BNP were log-transformed and z-transformed before analysis. Coronary artery stenoses
with stenotic narrowing 50% were deﬁned as signiﬁcant CAD. The extent of CAD was deﬁned as the number of
50% lesions. BMI, body mass index; eGFR, estimated glomerular ﬁltration rate; NAFLD, non-alcoholic fatty liver
disease; CAD, coronary artery disease; LVEF, left ventricular ejection fraction; BNP, brain natriuretic peptide; HR,
hazard ratio; CI, conﬁdence interval.
Table 2
Adjusted associations between CTRP1 quartiles and the incidence of major adverse cardiovascular events - results from
multivariable Cox regression analyses.
CTRP1 quartiles
Quartile
1
Quartile 2 Quartile 3 Quartile 4 ptrend-
value
Adjusteda hazard ratio
(95% CI)
1reference 1.98 [1.12e3.50];
p ¼ 0.019
2.18 [1.23e3.77];
p ¼ 0.005
1.86 [1.06e3.27];
p ¼ 0.030
0.036
Adjustedb hazard ratio
(95% CI)
1reference 1.83 [1.04e3.23];
p ¼ 0.037
2.16 [1.25e3.75];
p ¼ 0.006
1.80 [1.03e3.15];
p ¼ 0.038
0.041
Adjustment model a adjusts for age, sex, BMI, type 2 diabetes mellitus (T2DM), angiographically signiﬁcant coronary artery
disease (CAD), the extent of CAD, percentage of left ventricular ejection fraction (LVEF), hypertension, smoking, LDL cholesterol,
HDL cholesterol, and estimated glomerular ﬁltration rate (eGFR); model b adjusts for age, sex, BMI, type 2 diabetes mellitus
(T2DM), angiographically signiﬁcant coronary artery disease (CAD), hypertension, smoking, LDL cholesterol, HDL cholesterol,
estimated glomerular ﬁltration rate, (eGFR), ﬁbrinogen, and C-reactive protein (CRP). Age, BMI, LVEF, LDL cholesterol, HDL
cholesterol, eGFR, ﬁbrinogen, and CRP were log-transformed before included in multivariable Cox regression analyses.
A. Muendlein et al. / Data in brief 25 (2019) 104109 3stored at 80 C. C-reactive protein (CRP) was measured by particle enhanced immunological agglu-
tination (Roche, Switzerland) on a Hitachi Cobas 501. Serum CTRP1 levels were determined using a
commercial enzyme-linked immunosorbent assay (ELISA) kit (Biovendor, Brno, Czech Republic; article
number: RD191153100R).
During a mean follow-up period of 5.9 ± 2.2 years (with a total of 8 years) cardiovascular events
were recorded. Out of the 539 patients initially included in the present study, 15 subjects were lost to
follow-up. MACE was deﬁned as a three-point composite of cardiovascular death, nonfatal myocardial
infarction, and nonfatal stroke. Time and causes of death were regularly obtained from a national
survey (Statistik Austria, Vienna, Austria) or from hospital records.
Hazard ratios (HRs) and 95% conﬁdence intervals of the HRs were derived from univariable and
multivariable Cox proportional hazards models; log-transformed continuous variables were z-
A. Muendlein et al. / Data in brief 25 (2019) 1041094transformed for these analyses. P-values <0.05 were considered signiﬁcant. Statistical analyses were
performed with SPSS 25.0 for Windows (IBM, Armonk, New York, USA).
The present study has been approved by the Ethics Committee of the University of Innsbruck,
Austria, and written informed consent was given by all participants.
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